Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Herpes Simplex Virus
Last Updated: May 26, 2020; Last Reviewed: May 26, 2020
Note: Compared to acyclovir, valacyclovir has improved bioavailability and requires less frequent dosing.
Treating Orolabial Lesions (Duration: 5–10 Days)
|Chronic Suppressive Therapy
For Acyclovir-Resistant Mucocutaneous HSV infections
IV Foscarnet 80–120 mg/kg/day in 2–3 divided doses until clinical response (AI)
Alternative Therapy (Duration: ≥21–28 Days, Based on Clinical Response) (CIII):
Key: ART = antiretroviral therapy; HSV = herpes simplex virus; IV = intravenously; PO = orally
- CDC | 2015 STD Treatment Guidelines
- HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C
- AIDSinfo Patient Materials: What is an Opportunistic Infection?
- AIDSource | HIV-Related Conditions
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Adult and Adolescent OI Guidelines Archive